top of page

Roche’s Polivy was approved as first-line therapy for patients with DLBCL.

Roche has announced that the European Commission approved Polivy (polatuzumab vedotin) in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) as first-line therapy for patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

The approval was based on the Phase III POLARIX study. Polivy, in combination with R-CHP, showed improvement in the progression-free survival compared to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). After a median follow-up of 28.2 months, there was a 27% reduction in disease worsening or death in Polivy plus R-CHP arm compared to R-CHOP.

Further, the European Commission has given full approval to Polivy for treating adult patients with relapsed or refractory DLBCL who are not candidates for a hematopoietic stem cell transplant.

Polivy is an anti-CD79b antibody-drug conjugate (ADC). Most B-cells express CD79b protein, making it an attractive target for treating non-Hodgkin lymphoma (NHL). One in three non-Hodgkin lymphomas (NHL) cases is DLBCL, making it the most common form of NHL. Nearly 150,000 patients worldwide are diagnosed with DLBCL every year.


Recent Posts

See All


bottom of page